JP2000512282A - T細胞抗原受容体ペプチド - Google Patents
T細胞抗原受容体ペプチドInfo
- Publication number
- JP2000512282A JP2000512282A JP10500998A JP50099898A JP2000512282A JP 2000512282 A JP2000512282 A JP 2000512282A JP 10500998 A JP10500998 A JP 10500998A JP 50099898 A JP50099898 A JP 50099898A JP 2000512282 A JP2000512282 A JP 2000512282A
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- cell
- peptides
- amino acids
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.以下の配列: R1-A-B-A-R2 [配列中、 Aは疎水性アミノ酸または2〜10個のアミノ酸を含む 疎水性ペプチド配列であり; Bは荷電したアミノ酸であり; R1はNH2であり;そして R2はCOOHである] を有する、TCR機能を抑制するペプチド。 2.前記疎水性ペプチド配列が2〜6個のアミノ酸を含む、請求項1に記載のペ プチド。 3.前記疎水性ペプチド配列を形成するアミノ酸の少なくとも50%が疎水性アミ ノ酸である、請求項1または2に記載のペプチド。 4.前記BがArgおよびLysから選択される、請求項1〜3のいずれか1項に記載 のペプチド。 5.以下の配列: を有する、請求項1〜4のいずれか1項に記載のペプチド。 6.前記Bがアスパラギン酸およびグルタミン酸から選択される、請求項1〜3 のいずれか1項に記載のペプチド。 7.以下の配列: を有する、請求項6に記載のペプチド。 8.TCR機能を抑制するペプチドであって、TCR-α細胞内鎖から誘導され 、かつ以下の配列: を含む前記ペプチド。 9.以下の配列: R1-A-B-C-R2 [配列中、 Aは、0〜5個のアミノ酸からなるペプチド配列であり; Bはシステインであり; Cは2〜10個のアミノ酸からなるペプチド配列であり; R1はNH2であり;そして R2はCOOHである] を有する、TCR機能を抑制するペプチド。 10.前記Aが5個のアミノ酸を含むペプチド配列である、請求項9に記載のペプ チド。 11.前記Cが4または5個のアミノ酸からなるペプチド配列であり、かつ少なく とも1個の疎水性アミノ酸を含む、請求項9または10に記載のペプチド。 12.以下の配列: を有する、請求項9〜11のいずれか1項に記載のペプチド。 13.請求項1〜12のいずれか1項に記載のペプチドと製薬上許容される担体とを 含む治療用組成物。 14.T細胞が関与しているかまたはリクルートされている障害に罹患している被 験者の治療方法であって、請求項11に記載の治療用組成物の治療上有効な量 を該被験者に投与することを含んでなる前記方法。 15.化学的部分を細胞へ送達する方法であって、該細胞を、請求項1〜12のいず れか1項に記載のペプチドに結合させた該化学的部分に曝すことを含んでな る前記方法。
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU0389 | 1996-06-11 | ||
AU0392 | 1996-06-11 | ||
AU0393 | 1996-06-11 | ||
AUPO0392A AUPO039296A0 (en) | 1996-06-11 | 1996-06-11 | Novel immunomodulatory cd3-gamma chain peptides |
AUPO0391A AUPO039196A0 (en) | 1996-06-11 | 1996-06-11 | Novel immunomodulatory t-cell antigen receptor alpha chain peptides |
AU0394 | 1996-06-11 | ||
AUPO0389A AUPO038996A0 (en) | 1996-06-11 | 1996-06-11 | Novel immunomodulatory TCR-alpha chain peptides |
AU0390 | 1996-06-11 | ||
AUPO0393A AUPO039396A0 (en) | 1996-06-11 | 1996-06-11 | Novel immunomodulatory cd3-epsilon chain peptides |
AUPO0390A AUPO039096A0 (en) | 1996-06-11 | 1996-06-11 | Novel immunomodulatory t-cell antigen receptor clonotypic inter-chain disulphide peptides |
AU0391 | 1996-06-11 | ||
AUPO0394A AUPO039496A0 (en) | 1996-06-11 | 1996-06-11 | Novel immunomodulatory cd3-delta chain peptides |
PCT/AU1997/000367 WO1997047644A1 (en) | 1996-06-11 | 1997-06-11 | T cell antigen receptor peptides |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007003411A Division JP4294693B2 (ja) | 1996-06-11 | 2007-01-11 | T細胞抗原受容体ペプチド |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2000512282A true JP2000512282A (ja) | 2000-09-19 |
JP2000512282A5 JP2000512282A5 (ja) | 2004-12-09 |
JP4156671B2 JP4156671B2 (ja) | 2008-09-24 |
Family
ID=27542959
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50099898A Expired - Fee Related JP4156671B2 (ja) | 1996-06-11 | 1997-06-11 | T細胞抗原受容体ペプチド |
JP2007003411A Expired - Fee Related JP4294693B2 (ja) | 1996-06-11 | 2007-01-11 | T細胞抗原受容体ペプチド |
JP2008255970A Expired - Fee Related JP4452312B2 (ja) | 1996-06-11 | 2008-10-01 | T細胞抗原受容体ペプチド |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007003411A Expired - Fee Related JP4294693B2 (ja) | 1996-06-11 | 2007-01-11 | T細胞抗原受容体ペプチド |
JP2008255970A Expired - Fee Related JP4452312B2 (ja) | 1996-06-11 | 2008-10-01 | T細胞抗原受容体ペプチド |
Country Status (9)
Country | Link |
---|---|
US (1) | US7192928B1 (ja) |
EP (2) | EP0960119B1 (ja) |
JP (3) | JP4156671B2 (ja) |
AT (1) | ATE408617T1 (ja) |
AU (1) | AU739130B2 (ja) |
CA (1) | CA2257973C (ja) |
DE (1) | DE69739001D1 (ja) |
ES (1) | ES2314982T3 (ja) |
WO (1) | WO1997047644A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008500289A (ja) * | 2004-05-27 | 2008-01-10 | ノヴォザイムズ グロペップ リミテッド | 炎症性気道疾患の治療 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050070478A1 (en) * | 1996-06-11 | 2005-03-31 | Northern Sydney Area Health Services | T cell antigen receptor peptides |
ATE438405T1 (de) * | 2000-05-19 | 2009-08-15 | Univ Maryland | Verwendung von peptidantagonisten des zonulin zur behandlung von diabetes |
US10138276B2 (en) | 2009-09-30 | 2018-11-27 | Signablok, Inc. | Inhibition of TCR signaling with peptide variants |
US10238741B2 (en) | 2014-10-10 | 2019-03-26 | The Trustees Of Columbia University In The City Of New York | Nucleic acid constructs for presentation of CD4 and CD8 epitopes, cellular transfection and uses thereof |
EP3836951A1 (en) | 2018-08-13 | 2021-06-23 | Signablok, Inc. | Peptides and compositions for targeted treatment and imaging |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL92629A0 (en) * | 1989-12-10 | 1990-08-31 | Yeda Res & Dev | Direct binding of t-cell epitopes to mhc gene products on intact living antigen presenting cells and the use thereof for identifying epitopes causing autoimmune diseases and pharmaceutical compositions for treating such diseases |
WO1991009613A1 (en) * | 1989-12-22 | 1991-07-11 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Synthetic peptides as modulators of functional responses of intact cells |
US5200397A (en) | 1990-02-22 | 1993-04-06 | W. R. Grace & Co.-Conn. | Use of peptide analogs of thrombospondin for the inhibition of angiogenic activity |
US20020098197A1 (en) * | 1994-07-21 | 2002-07-25 | Alesandro Sette | Hla binding peptides and their uses |
DE69435292D1 (de) * | 1993-03-05 | 2010-06-17 | Epimmune Inc | Verfahren zur herstellung von immunogenen hla-a2.1-bindenden peptiden |
WO1995007707A1 (en) | 1993-09-14 | 1995-03-23 | Cytel Corporation | Alteration of immune response using pan dr-binding peptides |
US5936065A (en) * | 1993-12-06 | 1999-08-10 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
WO1995026980A2 (en) | 1994-04-01 | 1995-10-12 | Immulogic Pharmaceutical Corporation | Haptenated peptides and uses thereof |
US6100377A (en) * | 1994-06-10 | 2000-08-08 | The Trustees Of The University Of Pennsylvania | Constrained peptides |
EP0804469B1 (en) | 1995-01-16 | 2001-11-28 | Northern Sydney Area Health Service | T-cell affecting peptides |
-
1997
- 1997-06-11 AT AT97924813T patent/ATE408617T1/de not_active IP Right Cessation
- 1997-06-11 EP EP97924813A patent/EP0960119B1/en not_active Expired - Lifetime
- 1997-06-11 EP EP08016052A patent/EP2009018A3/en not_active Withdrawn
- 1997-06-11 US US09/202,305 patent/US7192928B1/en not_active Expired - Fee Related
- 1997-06-11 DE DE69739001T patent/DE69739001D1/de not_active Expired - Lifetime
- 1997-06-11 ES ES97924813T patent/ES2314982T3/es not_active Expired - Lifetime
- 1997-06-11 AU AU30193/97A patent/AU739130B2/en not_active Ceased
- 1997-06-11 CA CA002257973A patent/CA2257973C/en not_active Expired - Fee Related
- 1997-06-11 JP JP50099898A patent/JP4156671B2/ja not_active Expired - Fee Related
- 1997-06-11 WO PCT/AU1997/000367 patent/WO1997047644A1/en active IP Right Grant
-
2007
- 2007-01-11 JP JP2007003411A patent/JP4294693B2/ja not_active Expired - Fee Related
-
2008
- 2008-10-01 JP JP2008255970A patent/JP4452312B2/ja not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008500289A (ja) * | 2004-05-27 | 2008-01-10 | ノヴォザイムズ グロペップ リミテッド | 炎症性気道疾患の治療 |
Also Published As
Publication number | Publication date |
---|---|
CA2257973C (en) | 2010-02-02 |
JP4452312B2 (ja) | 2010-04-21 |
US7192928B1 (en) | 2007-03-20 |
EP0960119A1 (en) | 1999-12-01 |
EP2009018A2 (en) | 2008-12-31 |
JP2009062379A (ja) | 2009-03-26 |
EP2009018A3 (en) | 2009-03-18 |
EP0960119A4 (en) | 2005-01-12 |
JP4294693B2 (ja) | 2009-07-15 |
DE69739001D1 (de) | 2008-10-30 |
EP0960119B1 (en) | 2008-09-17 |
ES2314982T3 (es) | 2009-03-16 |
WO1997047644A1 (en) | 1997-12-18 |
ATE408617T1 (de) | 2008-10-15 |
AU739130B2 (en) | 2001-10-04 |
JP4156671B2 (ja) | 2008-09-24 |
CA2257973A1 (en) | 1997-12-18 |
JP2007145853A (ja) | 2007-06-14 |
AU3019397A (en) | 1998-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6203795B1 (en) | Pharmaceutical composition for the treatment or prevention of a malignant tumor | |
JP4452312B2 (ja) | T細胞抗原受容体ペプチド | |
EP0327283B1 (en) | Method of reducing immunoglobulin e responses | |
US6057294A (en) | Peptide | |
JPH04503812A (ja) | メラニン濃縮ホルモンおよびそれを用いた処置法 | |
KR101088740B1 (ko) | 샤페로닌 10을 이용한 면역억제 방법 | |
WO1992006117A1 (en) | Inhibiting unwanted immune responses | |
US6180600B1 (en) | CD8 antagonists | |
ES2307313T3 (es) | Nuevos polipeptidos, adn que codifican y utilizan estos polpeptidos. | |
KR100381711B1 (ko) | 펩티드들과그들을포함하는약학적조성물들 | |
KR100333148B1 (ko) | 당뇨질환예방제및치료제로서사용되는Vα14Jα281을함유하는가용성T-세포수용체α쇄및유도체 | |
JP2000511417A (ja) | D異性体のアミノ酸を含む免疫調節化合物 | |
US20100267651A1 (en) | T cell antigen receptor peptides | |
US5807714A (en) | Method of production of antigen-specific glycosylation inhibiting factor | |
JPH11507620A (ja) | 合成ペプチドおよびそれらを含有する医薬組成物 | |
US5872233A (en) | Mycoplasma arthritidis T-cell mitogen | |
US7078514B1 (en) | Chicken growth hormone releasing hormone receptor | |
Afshari et al. | EVALUATION OF SPECIFIC PURIFIED TCR EFFECT ON THE IMMUNOREGULATORY POTENTIAL OF TGF-B | |
WO1992021240A1 (en) | Suppressor t-cell hybridoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040416 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040416 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060801 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061031 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061218 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070111 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070724 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071022 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071126 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071120 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20071214 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080617 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080710 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110718 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |